Latest CSL Behring Stories
SANTA BARBARA, Calif., Dec. 6, 2010 /PRNewswire/ -- Direct Relief International announced today that CSL Behring has donated critically needed medical supplies to assist cholera patients in Haiti. The products will be used at Justinian University Hospital (JUH) in Cap-Haitien. JUH is the main public hospital for the entire northern sector of the country; the I.V. solutions and supplies will also be distributed to the numerous cholera treatment units (CTUs) that have been established in the...
KING OF PRUSSIA, Pa., Dec. 1, 2010 /PRNewswire/ -- CSL Behring announced today the availability of the next generation HeliTrax® System as part of a specially designed software platform for Apple's iPhone®, iPod touch®, or iPad(TM) devices. This enhanced system is designed to improve therapy management for people with hemophilia A who use CSL Behring's recombinant factor VIII (rFVIII). The new HeliTrax software is designed with an interface that ensures compatibility with both Lab...
LANSING, Mich., Nov. 9, 2010 /PRNewswire/ -- Bringing awareness to the need for early detection of a genetic disorder that can cause permanent and even fatal organ damage is the main theme of Alpha-1 Antitrypsin Deficiency Month in Michigan. The condition, known as Alpha-1, affects the lungs and liver in children and adults. Today representatives of the Alpha-1 Association, Michigan doctors who treat and advocate for patients with the disease and CSL Behring joined Governor Jennifer M....
KING OF PRUSSIA, Pa., Oct. 29 /PRNewswire/ -- To demonstrate its continued commitment to innovative immunoglobulin (Ig) research, CSL Behring announced today it has created the Interlaken Leadership Awards. This global awards program will provide monetary grants to advance medical research and knowledge about the potential role of immunoglobulin therapy in the treatment of neurologic disorders. From the management of primary immunodeficiency to the control of autoimmune and inflammatory...
ISTANBUL, Oct. 7 /PRNewswire/ -- Vivaglobin® (subcutaneous immunoglobulin [IgG]) (SCIg) is an effective and safe initial therapy for treatment-naive patients with primary immunodeficiency (PI) and may offer an attractive alternative to intravenous IgG (IVIg) therapy in the newly diagnosed, according to data presented today at the XIVth Meeting of the European Society for Immunodeficiencies. The study found that IgG replacement therapy initiated with Vivaglobin in patients with PI...
ISTANBUL, Oct. 7 /PRNewswire/ -- Privigen®, the first and only 10% liquid intravenous immunoglobulin (IVIg) therapy stabilized with proline, is effective and well tolerated in patients with several primary and secondary immunodeficiencies, according to data presented today at the XIVth Meeting of the European Society for Immunodeficiencies. Results also demonstrate that Privigen offers significant protection against infection. In a separate observational study, patients reported higher...
ISTANBUL, Oct. 7 /PRNewswire/ -- Hizentra® (IgPro20) provides primary immunodeficiency (PI) patients with a safe and effective alternative to other immunoglobulin therapies when given in equivalent doses, according to Phase III pivotal trial data presented today at the XIVth Meeting of the European Society for Immunodeficiencies (ESID). Hizentra, the first and only 20 percent SCIg developed for subcutaneous (i.e., under the skin) administration, can be stored at room temperature over its...
DULUTH, Minn., Sept. 25 /PRNewswire/ -- CSL Plasma, one of the world's largest collectors of human plasma, is honoring donors from the Duluth area today as part of a statewide observance of "Plasma Protein Therapies Month." According to Randy Furby, Senior Vice President and General Manager of CSL Plasma, Plasma Protein Therapies Month is helping raise awareness of rare genetic diseases treated with plasma-derived therapies while recognizing the generous contributions of plasma donors in...
KING OF PRUSSIA, Pa., Sept. 14 /PRNewswire/ -- CSL Behring announces the publication of its latest Key Issues Dialogue - Hereditary Angioedema (HAE) in the US. This ongoing series brings together thought leaders from the medical science and patient advocacy communities to examine critical issues affecting people with rare and serious diseases. The participants share and explore information and ideas that are important for patients, caregivers and healthcare providers. The current and...
LEIDEN, The Netherlands and SEATTLE, June 17, 2010 /PRNewswire/ -- ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced that it has entered into an agreement with CSL Behring for the clinical and commercial supply of plasma-based fibrinogen and thrombin, for the manufacturing of Fibrocaps(TM). CSL Behring is a leader in the plasma protein therapeutics industry and a subsidiary of CSL Limited (ASX: CSL), a global...
